Company intelligence / Profile preview

Kineactua

Seattle, Washington, USAazure.microsoft.com ↗

Ownership: Private
Development stage: Commercial

Overview

Kineta’s lead asset KVA12123, a VISTA-blocking monoclonal antibody, is in Phase 1/2 trials targeting mechanisms of cancer immune resistance. The company also had preclinical programs including an anti-CD27 agonist mAb. Prior to acquisition, it divested or terminated several other programs and partnerships to focus on its core immuno-oncology assets. Recent results have not been detailed publicly beyond ongoing early-phase studies

Therapeutic areas: OncologyNeurology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

Genentech – small molecule modulators collaboration/licensing deal ($5M upfront in past; now sold off prior to acquisition)Merck & Co. – inherited ALS/dementia drug candidates from Yumanity Therapeutics merger; rights sold off before TuHURA acquisitionSamsung Biologics – manufacturing partnership for monoclonal antibodies/immunotherapies

Beyond the preview

Go deeper on Kineactua.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kineactua.

Explore the full profile